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BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is amplified and overexpressed in 20–25% of breast cancers.
This study investigated circulating free DNA (cfDNA) for detection of HER2 gene amplification in patients with breast cancer.
METHODS: Circulating free DNA was extracted from plasma of unselected patients with primary breast cancer (22 before surgery and
68 following treatment), 30 metastatic patients and 98 female controls using the QIAamp Blood DNA Mini Kit (Qiagen). The ratio of
HER2 to an unamplified reference gene (contactin-associated protein 1 (CNTNAP1)) was measured in cfDNA samples by quantitative
PCR (qPCR) using SK-BR-3 cell line DNA as a positive control.
RESULTS: We validated the qPCR assay with DNA extracted from 23 HER2 3þ and 40 HER2-negative tumour tissue samples; the
results agreed for 60 of 63 (95.2%) tumours. Amplification was detected in cfDNA for 8 of 68 patients following primary breast
cancer treatment and 5 of 30 metastatic patients, but was undetected in 22 patients with primary breast cancer and 98 healthy female
controls. Of the patients with amplification in cfDNA, 10 had HER2 3þ tumour status by immunohistochemistry.
CONCLUSIONS: The results demonstrate for the first time the existence of amplified HER2 in cfDNA in the follow-up of breast cancer
patients who are otherwise disease free. This approach could potentially provide a marker in patients with HER2-positive breast
cancer.
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The human epidermal growth factor receptor 2 gene encodes a
185 kd cell surface glycoprotein (HER2), with intrinsic tyrosine
kinase activity, that plays a crucial role in regulating cell growth
and differentiation (Ullrich and Schlessinger, 1990). The protein is
overexpressed because of gene amplification in 20–25% of breast
cancers (Slamon et al, 1987), where it is a diagnostic marker for
aggressive disease and increased risk of metastasis and thus poor
prognosis (Ross and Fletcher, 1998). Over expression of HER2 is
not found in normal breast tissue or in benign breast lesions, but is
found inB30% of ductal carcinomas in situ (DCIS) (van de Vijver
et al, 1988). Breast cancer patients can be successfully treated with
the humanised monoclonal antibody trastuzumab (Herceptin,
Hoffman-La Roche Ltd, Basel, Switzerland) (Pegram et al, 1998),
and therefore accurate evaluation of HER2 status is essential for
better management.
Currently, two methods of determining HER2 status are used
routinely in clinical practice: immunohistochemistry (IHC), which
assesses expression of the HER2 protein on the cell surface, and
fluorescent in situ hybridisation (FISH), which detects amplifica-
tion of the HER2 gene (Pauletti et al, 2000; Bartlett et al, 2001;
Lebeau et al, 2001). Results can be affected by tissue fixation,
particularly for IHC and require standardised protocols with
quality assurance. Both of these methods require tumour biopsies,
removed by invasive techniques, and do not allow the monitoring
of minimal residual disease on follow-up. Patients are more likely
to respond to trastuzumab treatment for metastatic disease if they
have HER2 amplification than if they have HER2 overexpression
without amplification. Therefore, methods that detect copy
number increase may be better than protein overexpression assays
such as IHC (Vogel et al, 2001).
It was initially thought that HER2 amplification and over-
expression were stable over the course of disease and concordant
between primary tumour and metastases, and therefore patients
with low levels of expression at first presentation of breast cancer
are rarely given anti-HER2 (trastuzumab) treatment. However, in
2004, Meng et al (2004) demonstrated that HER2 gene amplifica-
tion can be acquired as breast cancer progresses; this concurs with
results using immunocytochemistry of circulating tumour cells
(Wulfing et al, 2006) showing that 50% of patients had evidence of
HER2-positive cells in the blood and that this correlated with
survival; the proportion of positive cells exceeded that expected by
IHC of the primary tumour. Quantitative PCR (qPCR) has been
used to determine HER2 amplification status in tumour DNA and
has shown similar results to FISH, and some discordance with
tissue-based IHC (Kulka et al, 2006; Monego et al, 2007); however,
the method has not been applied previously to circulating free
DNA (cfDNA).
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It is well established that higher concentrations of cfDNA can be
found in the blood of patients with cancer than in healthy people
(Goebel et al, 2005). However, this is not cancer specific as elevated
levels of cfDNA are also detected in patients with other
pathological conditions such as systemic lupus erythematosus,
rheumatoid arthritis and other conditions associated with
inflammatory processes (Davis and Davis, 1973; Koffler et al,
1973; Leon et al, 1981). A variety of methods are used for isolation
and quantitation of circulating DNA, with the Qiagen QIAamp
Blood Mini Kit (Qiagen, Hilden, Germany) and real-time PCR
quantification being most common (van der Vaart and Pretorius,
2010). Although most studies of cfDNA suggest that apoptosis
and/or necrosis are the predominant sources of cfDNA, active
release of cfDNA by living cells, and disturbances in the clearance
of this, are also plausible mechanisms (van der Vaart and
Pretorius, 2008). In this study, we developed a qPCR assay to
detect HER2 amplification in cfDNA. We compared contactin-
associated protein 1 (CNTNAP1), glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) and ribonuclease P RNA component H1
(RPPH1) as unamplified reference genes and showed that all three
were appropriate for measuring HER2 amplification using breast
cancer cell lines and normal DNA controls. We obtained blood
from unselected primary breast cancer patients, patients on follow-
up following primary breast cancer treatment, metastatic cases and
women with benign breast disease and healthy female controls and
analysed cfDNA for the presence of amplified HER2 DNA. We also
compared plasma results in 10 patients at the start of herceptin
treatment and while on therapy. The results suggest that plasma
may be used as a surrogate for a tumour biopsy in some patients.
MATERIALS AND METHODS
Patients and samples
The protocols were approved by the Riverside regional ethics
committee and conducted in accordance with the Declaration of
Helsinki. All patients gave written informed consent before
participation. Samples were blinded for analysis and patients
understood that the results would not be made available to them.
After obtaining statistical advice, we collected and analysed blood
samples from 22 women attending clinic who had just been
diagnosed with primary breast cancer, 6 patients with DCIS, 39
patients with benign breast disease and from 59 healthy female
volunteers. We also retrospectively analysed stored plasma
samples from 78 primary breast cancer patients on follow-up
following surgery, from a previously published cohort (Slade et al,
2009) and 30 patients with overt metastases (Table 1).
Following plasma separation by centrifugation at 850 g for
10min ( 2), plasma and cell pellets were separated and stored
directly at 80 1C. On thawing, plasma was centrifuged at 1500 g
for 5min and the supernatant was removed to a clean tube before
isolation of DNA.
DNA extraction
DNA samples used for assay development and validation were
from breast cancer cell lines MDA-MB-231 and SK-BR-3 (obtained
from ATCC, Manassas, VA, USA) and human genomic DNA
(Roche Applied Science, West Sussex, UK), comprising a pool of
B100 blood donors from both sexes.
Lymphocyte and plasma cfDNA were extracted using the
QIAamp Blood DNA Mini Kit (Qiagen) according to the blood
and body fluid protocol as described previously (Page et al, 2006;
Shaw et al, 2011).
For analysis of tumour samples, 5 mm haematoxylin and eosin-
stained formalin-fixed and paraffin-embedded (FFPE) tissue
sections were reviewed by a pathologist and foci of tumour cells
were isolated by manual microdissection. DNA was extracted by
standard proteinase K digestion, phenol–chloroform extraction
and ethanol precipitation. DNA pellets were re-suspended in 50 ml
sterile ultrapure water.
Quantitative PCR detection of HER2 gene amplification
Primers and a FAM-labelled minor groove binder (MGB) TaqMan
probe were targeted to HER2 (target; locus 17q21.1), CNTNAP1
(unamplified reference (based on data available at the start of the
study at http://www.sanger.ac.uk/genetics/CGP/cosmic), locus
17q21) and GAPDH (unamplified reference, locus 12p13.1), as
described previously (Shaw et al, 2011), and RPPH1 (unamplified
reference, locus 14q21) (forward primer: 50-CGGAGGGAAGCT
CATCAGTG-30, reverse primer: 50-GACATGGGAGTGGAGTGA
CA-30, MGB probe: 50-CACGAGCTGAGTGCGT-30). All assays
were carried out in triplicate on MicroAmp Fast plates (Applied
Biosystems, Foster City, CA, USA) in a 10ml reaction volume
comprising: 5 ml TaqMan Universal Fast Mastermix (Applied
Biosystems), 600 nmol forward and reverse primers, 200 nmol
FAM-MGB TaqMan probe and 3.6 ml template DNA. A human
genomic DNA sample (Roche Applied Science) was included in
each experiment together with SK-BR-3 cell line DNA (as a positive
Table 1 Characteristics of the primary tumour from breast cancer
patients
Primary breast
cancer
following
treatment
Pre-treatment
primary
breast cancer
Metastatic
breast
cancer
No. % No. % No. %
Histology
Invasive ductal 55 71 13 59 26 87
Invasive lobular 8 10 4 18 3 10
Other/mixed invasive 15 19 5 23 1 3
Lymph node status
Positive 48 62 6 27 19 63
Negative 29 37 12 55 5 17
Unknown 1 1 4 18 6 20
Tumour size
T1 43 55 9 41 10 33.3
T2 24 31 8 36 7 23.4
T3 8 10 1 5 3 10
T4 0 0 0 0 0 0
Unknown 3 4 4 18 10 33.3
Tumour grade
I 5 6 3 13.6 0 0
II 31 40 16 72.7 17 57
III 41 53 2 9.1 9 30
Unknown 1 1 1 4.5 4 13
Hormone receptor status
ER positive 50 64 21 95 20 66.7
ER negative 28 36 1 5 10 33.3
PgR positive 34 43 21 95 16 54
PgR negative 39 51 1 5 12 40
Unknown PgR status 5 6 0 0 2 6
HER2 status
Positive 37 47 2 9 18 60
Negative 41 53 20 91 12 40
Total 78 100 22 100 30 100
Abbreviations: ER¼ estrogen; PgR¼ progesterone; HER2¼ human epidermal
growth factor receptor 2. The American Joint Committee on Cancer (AJCC) staging
system was used to classify tumour size.
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control for HER2 amplification) and sterile water as a no template
control. Reactions were run on Applied Biosystems thermal cyclers
(Step One and 7900 Fast) with an initial activation step at 95 1C for
20 s followed by 50 cycles of 95 1C for 1/3 s and 60 1C for 20/30 s
(Step One/7900 Fast).
To determine HER2 gene amplification, the DCt was determined
(average Ct value of the target gene minus the average Ct value
of the reference gene) and used to calculate the DDCt for each
DNA sample, using the mean relative quantitation (RQ) value
derived from a panel of 49 normal lymphocyte DNA samples
(RQ¼ 1.003±0.086) as the experimental calibrator. The RQ
values were calculated as 2DDCt. The Z-score was calculated as
follows: Z-score¼ (DCt patient sampleDCt average normal
lymphocyte panel)/average s.d. of normal lymphocyte panel.
A negative Z-score value indicated significant amplification
(3.30¼ 99.9% confidence, 2.60¼ 99% confidence and 1.96¼
95% confidence).
Statistical analysis was performed using GraphPad Prism
version 5.0 (San Diego, CA, USA). Unpaired t-tests, followed by
Mann–Whitney tests, were used to compare two patient groups.
The Dunn’s multiple comparison test was used to compare s.d.
values from all cfDNA samples.
HER2 immunohistochemistry
HER2 status was obtained from the patient records where known.
The HER2 status of the primary tumour was not known for 63 of
the 130 patients as their diagnosis predated the introduction of
HER2 testing in the United Kingdom in October 2006. Immuno-
histochemistry was performed using the monoclonal antibody
CB11 (Novocastra, Newcastle, UK) following established guidelines
(Walker et al, 2008). All IHC slides were reviewed by one of the
authors (RAW).
RESULTS
Reference gene selection and validation of HER2
amplification in cell lines and FFPE tumour DNA
We first measured the ratio of HER2 to three separate reference
loci, CNTNAP1, RPPH1 and GAPDH, in a panel of 49 lymphocyte
DNA samples isolated from healthy female controls. The mean RQ
values were 1.102±0.358 for CNTNAP1, 1.000±0.120 for GAPDH
and 0.565±0.300 for RPPH1, confirming a 1 : 1 ratio of HER2 to
CNTNAP1 and GAPDH in normal lymphocyte DNA samples. We
next surveyed DNA isolated from two breast cancer cell lines of
known HER2 amplification status (SK-BR-3 (amplified) and MDA-
MB-231 (unamplified)), using the qPCR assay. SK-BR-3 showed
high amplification (mean RQ¼ 14.3) and MDA-MB-231 showed no
amplification (mean RQ¼ 0.8). These results were reproducible
using 10 ng of genomic DNA, when the starting DNA was diluted
250-fold (data not shown), and over 3, 5 and 9 independent
replicates (Figure 1A).
We next validated the assay using DNA isolated by microdissec-
tion from FFPE tissue sections from 63 tumours: 23 were scored as
HER2 3þ and 40 as HER2 negative by IHC. RQ values ofX2.0 (Suo
et al, 2004) and X2.7 (Kulka et al, 2006) have been considered
previously to be positive for HER2 gene amplification. As RQ values
of X2.1 all showed negative Z-scores of p3.30 (99.9% confidence
interval), we selected this as the cutoff for HER2 amplification. The
RQ results agreed with the IHC results for 60 (95.2%) of the 63
samples. Discordant findings were for one HER2 3þ tumour that
showed no amplification in the corresponding DNA (RQ¼ 1.84) and
two tumours, reported as HER2 negative by IHC, that showed
amplification in microdissected foci of tumour cells (RQ values of
2.31 and 2.22, respectively). Results were consistent when the tumour
DNA was diluted 250-fold (Figure 1B).
Detection of HER2 gene amplification in cfDNA
We first screened cfDNA from 59 healthy female controls, 39
patients with benign breast disease, 6 cases of DCIS and 63 normal
lymphocyte DNA samples. None showed RQ values of X2.1, our
cutoff for HER2 amplification, although the RQ value wasB2.0 for
cfDNA from one healthy control and two benign breast disease
patients, indicating potential amplification. None of the 22
untreated primary breast cancer patients had HER2 amplification
in cfDNA, although only two had a HER2-positive tumour by IHC.
Clear evidence of HER2 amplification was detected in cfDNA of 13
breast cancer patients: 8 of 78 patients on follow-up following
primary breast cancer treatment and 5 of 30 metastatic patients
(Figure 2). The mean RQ value for the 13 positive cfDNA
samples was 5.56, well above the RQ threshold. The RQ values
were very similar using results from both a panel of 49 normal
lymphocyte DNA samples and commercially available Human
Genomic DNA to calculate DDCt and hence RQ. Although RQ
values of cfDNA samples derived from breast cancer patients were
spread over a broader range than for other samples (Figure 2),
Dunn’s multiple comparison test showed no significant difference
between the s.d. values of patients and controls. When we
compared the number of samples with amplification in each
group, there was a statistically significant difference between
pooled healthy and benign patient samples and both primary
patients on follow-up and metastatic patients (P¼ 0.0415 and
o0.0001, respectively, Figure 2).
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Figure 1 Validation of HER2 amplification in cell lines and FFPE tumour
DNA. (A) Mean HER2 RQ for SK-BR-3 (HER2 amplified) and MDA-
MB-231 (unamplified) cell line DNA, measured using 3, 5 and 9
independent replicates. (B) Mean HER2 RQ for three HER2 IHC-negative
(patients 1–3) and three HER2 3þ (patients 3–6) tumour DNA samples.
DNA was diluted 50-, 100- and 250-fold. Bars show the mean RQ at each
dilution of DNA±s.d.
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Comparison of cfDNA with tumour phenotype
We reviewed all patient records for the HER2 status of the primary
tumour and performed IHC in 63 cases for whom FFPE tissue was
available. In total, there were 39 of 90 primary patients (22
presurgical and 68 on follow-up) and 18 of 30 metastatic patients
with a HER2 3þ tumour status by IHC. When we compared
cfDNA results with the corresponding primary tumour IHC, we
found that six of the eight primary patients on follow-up and all
five metastatic patients with amplification in cfDNA had HER2 3þ
tumour status (Figure 3A). However, not all patients with HER2
3þ tumour status showed amplification in cfDNA. There were
2 presurgical primary breast cancer patients, 31 primary breast
cancer patients on follow-up and 13 patients with overt metastases
whose tumours were HER2 3þ who had negative cfDNA tests.
There were also two primary patients on follow-up and one
metastatic patient with HER2 2þ tumour status who had a
negative cfDNA test. In the eight primary patients on follow-up,
we next compared patients with amplification in cfDNA with
node status: 6 were node positive and 2 were node negative
(Figure 3B). There was no association between patients with
HER2 amplification in cfDNA and any other clinicopathological
variable. There were 12 primary breast cancer patients and 12
patients with metastatic disease who had completed trastuzumab
therapy before venepuncture, and all were negative for HER2
amplification in cfDNA apart from 3 metastatic breast cancer
patients who had RQ values of 3.71, 6.02 and 16.97 in cfDNA
(Table 2). To investigate this further, we recruited 10 patients,
before commencing treatment with trastuzumab, and compared
paired blood samples for these taken before treatment and 3 to 4
months after starting therapy. Of the 10 patients, 6 had a positive
plasma test by RQ, which was consistent both before treatment and
while on therapy, and 4 patients were negative by RQ in both
samples.
DISCUSSION
This study investigated the potential utility of cfDNA as a source
for detection of HER2 gene amplification in patients with breast
cancer. The mean RQ value achieved by normal diploid
lymphocyte samples was 1.08 by the assay we have used and
therefore we chose to use RQ X2.1 for HER2 amplification in
order to reduce the chances of any false-positive results (Suo et al,
2004). The RQ assay was specifically able to detect HER2 gene
amplification, as the reference gene chosen (CNTNAP1) lies on the
same chromosome as HER2. There is clearly potential for changes
in copy number in tumour DNA, and hence it would be preferable
to use a panel of reference genes to detect amplification, but
limiting cfDNA quantities prevent using such an approach. Our
RQ assay showed good correlation with results from IHC (95.2%),
using DNA isolated by microdissection from 63 FFPE tumour
tissue samples. Moreover, the assay was reproducible between
replicate experiments, and when using a 250-fold dilution of
tumour DNA. Where amplification was detected, it was specific for
HER2 rather than polysomy 17, as RQ values were similar using
both CNTNAP1 and GAPDH as the reference genes (data not
shown). Polysomy 17 has been shown to have no effect on HER2
mRNA levels or protein expression (Dal Lago et al, 2006;
Fehm et al, 2007).
The results have shown that it is possible to detect HER2
amplification in cfDNA of some patients on follow-up following
primary breast cancer treatment despite the fact that they had no
evidence of metastatic disease, either at the time of sampling or
46 years after. This is in sharp contrast to the 39 patients with
benign breast disease and 59 healthy women, who showed no
evidence of HER2 amplification in cfDNA using a cutoff for RQ of
2.1. Of the 78 breast cancer patients on follow-up after primary
treatment, 12 had received trastuzumab before venepuncture. In
these patients, previous trastuzumab therapy was associated with a
negative plasma qPCR test. Of the 30 patients with metastatic
disease, 12 had received trastuzumab treatment: 10 of these were
negative by RQ and 2 had RQ values of 6.02 and 16.97 in cfDNA
(Table 2). We also compared cfDNA results in 10 primary breast
cancer patients before commencement of trastuzumab treatment
and while on therapy. All 10 patients showed consistent results
between their paired samples (6 were positive by RQ and 4 were
negative). Together, the results suggest that a change from positive
to negative RQ results might indicate successful therapy, as was
suggested in a recent study of 28 patients (Sorensen et al, 2010).
However, the findings need confirmation in a larger series,
comparing RQ results for cfDNA pre- and post-trastuzumab
therapy and with clinical response.
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Figure 2 Detection of HER2 gene amplification in cfDNA of breast
cancer patients. Lymphocyte (L) and plasma (P) cfDNA RQ values for all
samples using 49 normal lymphocyte DNA samples as a reference panel to
calculate DDCt and hence RQ. Unpaired t-tests were performed to
compare pooled controls and benign samples with both primary and
metastatic patient groups.
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Figure 3 Relationship between HER2 amplification in cfDNA and
patient node and HER2 3þ tumour status. (A) Circulating free DNA RQ
values for primary patients on follow-up by node status. (B) Circulating free
DNA RQ values for all primary patients on follow-up and metastatic
patients with HER2 3þ tumour status by IHC.
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Not all patients with HER2 3þ tumours by IHC had detectable
gene amplification in cfDNA. This is perhaps not surprising as a
majority of patients were sampled several years after removal of
their primary breast cancer and therefore may have been cured.
For the eight primary breast cancer patients with HER2 amplifica-
tion in cfDNA, the follow-up time is insufficient to inform us as to
whether the presence of circulating amplified HER2 DNA is
predictive of recurrent disease. Other studies have shown that
some patients, whose tumours were HER2 negative, show
circulating tumour cells (CTCs) that express HER2, and circulating
HER2 extracellular domain (ECD) is also found in similar
groups of patients (Fehm et al, 2007). In one study, many patients
with metastatic disease had CTCs expressing HER2, but most of
these patients were end stage with extensive metastatic disease,
and had received multiple courses of chemotherapy (Vogel et al,
2001). The authors suggest that chemotherapy exerts a selective
pressure, allowing the emergence of HER2-positive cells.
Several groups have now presented evidence that HER2-
positive CTCs can be detected in patients with HER2-negative
primary breast cancer during follow-up (Braun et al, 2001; Zidan
et al, 2005; Wulfing et al, 2006; Fehm et al, 2010). The data
presented in this publication support these findings, as
HER2-amplified cfDNA was detected in two HER2-negative
patients following primary breast cancer treatment. It has
been reported that this indicates a poor prognosis (Wulfing
et al, 2006); it is not clear whether these cells represent a switch in
phenotype or a subgroup of pre-existing cells within the primary
tumour.
We have recently compared cfDNA and CTC detection in 19
other patients on follow-up (median 3.5 years) (Shaw et al, 2011).
Of these, 17 demonstrated no evidence of CTCs, 1 patient had 1
CTC and 1 patient had 3 CTCs. Also, eight patients had HER2 3þ
tumours and four of these had HER2 amplification in cfDNA, but
these did not overlap with the two CTC-positive patients. None of
Table 2 HER2 RQ results in tumour and cfDNA of 30 metastatic breast cancer patients
Trastuzumab before
blood sample
RQ value
Patient HER2 IHC (disease status Jan 2011) Date of blood sample Plasma Tumour
1 3+ No 08/2008 0.87 NA
2 3+ Yes 05/2007 6.02 35.30
3 3+ Yes (S) 04/2007 0.29 3.72
4 3+ Yes 2002 0.48 23.96
5 3+ No 07/2008 1.66 4.23
6 3+ Yes (S) 04/2007 0.53 NA
7 3+ Yes (L) 03/2007 0.11 16.58
8 3+ Yes 03/2007 16.97 6.52
9 3+ Yes 03/2007 3.71 81.74
10 3+ Yes 05/2007 0.03 NA
11 3+ Yes 2002 1.62 2.24
12 3+ No 2002 2.61 7.99
13 3+ Yes 2002 0.46 9.15
14 3+ No 2002 15.28 4.76
15 3+ Yes 07/2008 1.26 22.60
16 3+ Yes 07/2008 1.49 1.99
17 Neg Unknown 07/2008 1.18 NA
18 Neg Unknown (P) 08/2008 1.95 NA
19 Neg Unknown 08/2008 5.41 2.10
20 2+ Unknown 08/2008 1.86 2.42
21 Neg Unknown 2001 0.33 0.85
22 Neg No 2002 0.87 0.83
23 Neg No 2002 0.61 8.53
24 Neg No 2002 0.93 1.10
25 Neg No 2002 0.36 NA
26 Neg No 2002 1.73 NA
27 Neg No (P) 04/2007 1.54 NA
28 Neg No 06/2007 1.12 NA
29 3+ No (H) 08/2009 1.07 NA
30 3+ No (H) 08/ 2009 1.96 NA
Abbreviations: HER2¼ human epidermal growth factor receptor 2; RQ¼ relative quantitation; cfDNA¼ circulating free DNA; IHC¼ immunohistochemistry; Neg¼ negative;
NA¼ no tissue available. Disease status: S¼ stable; L¼ lapatinib; P¼ disease progressing; H¼ adjuvant herceptin. Where no disease status indicated, deceased. Showing RQ
value for DNA extracted from microdissected foci of the primary tumour and from cfDNA.
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Figure 4 Copy number variation in cfDNA in the HER2 gene interval
detected by SNP 6.0 Array. Top panel paired plasma and leukocyte DNA
samples for 2 HER2 IHC-negative patients, and lower panel paired plasma
and leukocyte DNA samples for 2 HER2 3þ patients. Each vertical bar
represents one copy number (CN) marker and its value is as inferred by
the colour scale, with blue showing amplification and red showing deletion.
The exons and introns of the HER2 gene are indicated at the bottom of the
diagram, with the location of the qPCR assay (exon 16) marked in red.
L, leukocyte DNA; P1, plasma cfDNA.
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the patients have relapsed thus far, but results in this separate
cohort confirm that HER2 amplification is detectable in plasma of
patients on follow-up. We have also analysed cfDNA of 65 breast
cancer patients for copy number variations using Affymetrix (High
Wycombe, UK) SNP 6.0 Array (JA Shaw et al, in preparation). In
all, 50 patients were on follow-up and overlap with patients in this
study. The normal leukocyte DNA samples and cfDNA of 37
HER2-negative patients showed mostly diploid copy number
(mean copy number (CN) state¼ 2.0), whereas plasma samples
of 13 HER2 3þ patients showed a mean CN state of 2.5–3.0 by
smooth signal, indicating a low level of amplification (Figure 4).
Hence, we have confirmed the ability to detect HER2 amplification
in cfDNA by another method.
In conclusion, this study has demonstrated the existence of
circulating amplified HER2 DNA, both in the follow-up of breast
cancer patients otherwise disease free and in patients with
metastatic disease. The follow-up time is insufficient to inform
us as to whether the presence of circulating amplified HER2 DNA
is predictive of recurrent disease. The results in cfDNA do not
always correlate with the primary tumour, suggesting that HER2
gene amplification can be acquired as breast cancer progresses due
to emergence of HER2-positive cells. Future studies will focus on
examining the relationship between cfDNA and CTC HER2
expression and determining the reason for changes in HER2
status over time; we also hope to establish the prognostic
significance of finding circulating HER2-amplified DNA in patients
on follow-up and compare the different methods for monitoring
minimal residual disease during adjuvant therapy in patients with
breast cancer.
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